Macrolides use and the risk of sudden cardiac death

References

• Hopkins S. Clinical toleration and safety of azithromycin. Am J Med. 1991;91(3A):40S–45S. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1656742
   Google Scholar
• Ioannidis JP, Contopoulos-Ioannidis DG, Chew P, et al. Meta-analysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for upper respiratory tract infections. J Antimicrob Chemother. 2001;48:677–689.
   PubMed Web of Science ®Google Scholar
• Hancox JC, Hasnain M, Vieweg VR, et al. Erythromycin, QTc interval prolongation, and torsade de pointes: Case reports, major risk factors and illness severity. Ther Adv Infect Dis. 2014;2:47–59.
   PubMedGoogle Scholar
• Ray WA, Murray KT, Hall K, et al. Azithromycin and the risk of cardiovacular death. N Engl J Med. 2013;368:1704–1712.
   PubMed Web of Science ®Google Scholar
• Svanstrom H, Pasternak B, Hviid A. Use of clarithromycin and roxithromycin and risk of cardiac death: cohort study. BMJ. 2014;349:g4930.
   PubMed Web of Science ®Google Scholar
• Ray WA, Murray KT, Meredith S, et al. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med. 2004;351:1089–1096.
   PubMed Web of Science ®Google Scholar
• Louie R. Azithromycin and the risk of cardiovascular death. N Engl J Med. 2012;367:774.
   PubMed Web of Science ®Google Scholar
• Milberg P, Eckardt L, Bruns HJ, et al. Divergent proarrhythmic potential of macrolide antibiotics despite similar QT interval prolongation: Fast 3 phase repolarization prevents early after depolarizations and torsades de pointes. J Pharmacol Exp Ther. 2002;303:218–225.
   PubMed Web of Science ®Google Scholar
• Volberg WA, Koci BJ, Su W, et al. Blockade of human cardiac potassium channel human ether-a-Go-Go-related gene (HERG) by macrolide antibiotics. J Pharmacol Exp Ther. 2002;302:320–327.
   PubMed Web of Science ®Google Scholar
• Katapadi K, Kostandy G, Katapadi M, et al. A review of erythromycin-induced malignant tachyarrhythmia–torsade de pointes. A case report. Angiology. 1997;48:821–826.
   PubMed Web of Science ®Google Scholar
• Shaffer D, Singer S, Korvick J, et al. Concomitant risk factors in reports of Torsades de Pointes associated with macrolide use: review of the United States food and drug administration adverse event reporting system. Clin Infect Dis. 2002;35:197–200.
   PubMed Web of Science ®Google Scholar
• Mosholder AD, Mathew J, Alexander JJ, et al. Cardiovascular risks with azithromycin and other antibacterial drugs. N Engl J Med. 2013;368:1665–1668.
   PubMed Web of Science ®Google Scholar
• Cheng YJ, Nie XY, Chen XM, et al. The role of macrolide antibiotics in increasing cardiovascular risk. J Am Coll Cardiol. 2015;66:2173–2184.
   PubMed Web of Science ®Google Scholar
• Schembri S, Williamson PA, Short PM, et al. Cardiovascular events after clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort studies. BMJ. 2013;346:f1235. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23525864/
   Google Scholar
• Jespersen CM, Als-Nielsen B, Damgaard M, et al. Randomized placebo controlled multicenter trial to assess short clarithromycin for patients with stable coronary heart disease: CLARICOR trial. BMJ. 2006;332:22–27.
   PubMed Web of Science ®Google Scholar
• Winkel P, Hilden J, Fischer HJ, et al. Excess sudden cardiac deaths after short-term clarithromycin administration in the CLARICOR trial: why is this so, and why are statins protective? Cardiology. 2011;118(1):63–67.
   PubMed Web of Science ®Google Scholar
• Bochem AE, Van Der Valk FM, Tolani S, et al. Increased systemic and plaque inflammation in ABCA1 mutation carriers with attenuation by Statins. Arterioscler Thromb Vasc Biol. 2015;35:1663–1669.
   PubMed Web of Science ®Google Scholar
• Ahmadi A, Leipsic J, Blankstein R, et al. Do plaques rapidly progress prior to myocardial infarction? The interplay between plaque vulnerability and progression. Circ Res. 2015;117:99–104.
   PubMed Web of Science ®Google Scholar
• Gelfand EV, Cannon CP. Antibiotics for secondary prevention of coronary artery disease: an ACES hypothesis but we need to PROVE IT. Am Heart J. 2004;147:202–209.
   PubMed Web of Science ®Google Scholar
• Alviar CL, Echeverri JG, Jaramillo NI, et al. Infectious atherosclerosis: is the hypothesis still alive? A clinically based approach to the dilemma. Med Hypotheses. 2011;76(4):517–521.
   PubMed Web of Science ®Google Scholar
• Gieffers J, Solbach W, Maass M. In vitro susceptibility and eradication of Chlamydia pneumoniae cardiovascular strains from coronary artery endothelium and smooth muscle cells. Cardiovasc Drugs Ther. 2001;15:259–262.
   PubMed Web of Science ®Google Scholar
• Melissano G, Blasi F, Esposito G, et al. Chlamydia pneumoniae eradication from carotid plaques: results of an open, randomised treatment study. Eur J Vasc Endovasc Surg. 1999;18:355–359.
   PubMed Web of Science ®Google Scholar
• Gupta S, Leatham EW, Carrington D, et al. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation. 1997;96:404–407.
   PubMed Web of Science ®Google Scholar
• Andraws R, Berger JS, Brown DL, et al. Effects of antibiotic therapy on outcomes of patients with coronary artery disease: a meta-analysis of randomized controlled trials. Jama. 2005;293:2641–2647.
   PubMed Web of Science ®Google Scholar
• Danesh J. Antibiotics in the prevention of heart attacks. Lancet. 2005;365:365–366.
   PubMed Web of Science ®Google Scholar
• Grayston JT, Kronmal RA, Jackson LA, et al. Azithromycin for the secondary prevention of coronary events. N Engl J Med. 2005;352:1637–1645.
   PubMed Web of Science ®Google Scholar
• Gluud C, Als-Nielsen B, Damgaard M, et al. Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease. Cardiology. 2008;111:280–287.
   PubMed Web of Science ®Google Scholar
• Rao GA, Mann JR, Sboaibi A, et al. Azithromycin and levofloxacin use and increased risk of cardiac arrhythmia and death. Ann Fam Med. 2014;12:121–127.
   PubMed Web of Science ®Google Scholar
• Svanström H, Pasternak B, Hviid A. Use of azithromycin and death from cardiovascular causes. N Engl J Med. 2013;368:1704–1712.
   PubMed Web of Science ®Google Scholar
• Singanayagam A, Short P, Williamson P, et al. S27 Cardiovascular events following clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort studies. Thorax. 2012;67:A15–A16.
   Web of Science ®Google Scholar
• Lee SM, Nguyen D, Hu Z, et al. Kcne2 deletion promotes atherosclerosis and diet-dependent sudden death. J Mol Cell Cardiol. 2015;87:148–151.
   PubMed Web of Science ®Google Scholar
• Abbott GW, Sesti F, Splawski I, et al. MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell. 1999;97(2):175–187.
   PubMed Web of Science ®Google Scholar
• Grandy JK. Clinical update: macrolides and cardiovascular death. PJPPS. 2013;1(2):14–18. Available from: http://publicationslist.org/data/john.grandy/ref-29/PJPPS-13-025%20Grandy%20.pdf
   Google Scholar